.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Deloitte
Argus Health
Baxter
Covington
Teva
Healthtrust
Fuji
Cipla

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,238,076

« Back to Dashboard

Which drugs does patent 9,238,076 protect, and when does it expire?


Patent 9,238,076 protects BYDUREON, BYDUREON PEN, BYDUREON BCISE, and FARXIGA, and is included in three NDAs.

This patent has twenty-seven patent family members in twenty-two countries.

Summary for Patent: 9,238,076

Title:Polymer-based sustained release device
Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Inventor(s): Wright; Steven G. (Madeira, OH), Christensen; Troy (Mason, OH), Yeoh; Thean (Salem, CT), Rickey; Michael E. (Morrow, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Fineman; Mark (San Deigo, CA), Smith; Christine (San Diego, CA), Ong; John (San Diego, CA), Lokensgard; David M. (San Diego, CA), Costantino; Henry R. (Woodinville, WA)
Assignee: Alkermes Pharma Ireland Limited (Dublin, IE) Amylin Pharmaceuticals, LLC (San Diego, CA)
Application Number:13/743,117
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca AbBYDUREONexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-001Jan 27, 2012RXYesYes► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES► Subscribe
Astrazeneca AbBYDUREON PENexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-002Feb 28, 2014RXYesYes► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES► Subscribe
Astrazeneca AbBYDUREON BCISEexenatideSUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS209210-001Oct 20, 2017RXYesYes► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES► Subscribe
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-001Jan 8, 2014RXYesNo► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES► Subscribe
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-002Jan 8, 2014RXYesYes► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,238,076

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,563,871Polymer-based sustained release device► Subscribe
8,877,252Polymer-based sustained release device► Subscribe
8,617,613Polymer-based sustained release device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,238,076

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria531374► Subscribe
Australia2004319756► Subscribe
BrazilPI0418702► Subscribe
Canada2560981► Subscribe
China1968700► Subscribe
Cyprus1112156► Subscribe
Cyprus1116337► Subscribe
Germany122012000028► Subscribe
Denmark1734971► Subscribe
Denmark2409707► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Medtronic
Covington
US Army
Julphar
Fuji
Federal Trade Commission
Cipla
McKinsey
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot